Appointment to the Board

Source BioScience

("Source BioScience", "the Group")

Appointment to the Board

3 July 2014, Nottingham, UK - Source BioScience plc (LSE: SBS) the international laboratory services and products business, announces that Pam Liversidge, OBE will join the Board as a Non-Executive Director with immediate effect.

Pam is a Chartered Mechanical Engineer and Fellow of the Royal Academy of Engineering with over 30 years' experience in the manufacturing and engineering industries. She has significant experience in senior leadership roles across a broad spectrum of companies and other organisations including Chesterfield Royal Foundation Trust Hospital and Sheffield Hallam University. Pam was the first woman to be elected as President of the Institution of Mechanical Engineers and as Master of the Company of Cutlers in Hallamshire.

Laurie Turnbull, Chairman, said: "I am delighted to welcome Pam to the Board. Her considerable knowledge of the manufacturing and engineering industries will be invaluable following the acquisitions of Inverclyde Biologicals and Vindon during 2013. She will also bring experience and an important, additional skill base to the Board as we continue with the implementation of the Group's growth strategy."

Further information required to be disclosed: Mandall Engineering Ltd entered into administration in June 2006, while Mrs Liversidge was a director, and was ultimately wound up in March 2008 by means of a creditors' voluntary liquidation. No further information is required to be disclosed pursuant to paragraph 9.6.13 of the Listing Rules.

-Ends-

For further information, please contact:

Source BioScience plc

Dr Nick Ash, CEO

Tel: +44 (0) 115 973 9010

Email: [email protected]

www.sourcebioscience.com

Instinctif Partners (PR Agency to Source BioScience)

Melanie Toyne-Sewell / Jen Lewis / Emma Barlow

Tel: +44 (0)20 7457 2020

Email: [email protected]

About Source BioScience:

Source BioScience is a trusted provider of state-of-the-art products and services to the healthcare and clinical, life and applied scientific and biopharma industries. It is an international business with centres in four countries and customers in over 90 countries. The Group offers a complementary portfolio of products and services that share common technologies, lab processes, infrastructure and expertise. These include clinical diagnostics, genomics, proteomics, drug discovery and development research as well as controlled environment storage and testing services for a diverse range of markets. These products and services are provided to a large and diverse customer base including the top 50 pharmaceutical companies, leading universities and research institutes worldwide, the UK NHS and other healthcare providers. The Group is listed on the Premium Main Market of the London Stock Exchange (LSE: SBS).